TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31642245
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose bortezomib (1.0-1.3 mg/m2) on day 1, day 4, day 8, and day 11, with 21 days as a chemotherapy cycle.
Study: 31642245
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose bortezomib (1.6 mg/m2) on day 1, day 8, day 15, and day 22, with 35 days as a chemotherapy cycle.
Study: 15119752
Drug: Epinastine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinastine 10 mg plus pseudoephedrine 120 mg
Study: 11694895
Drug: 60 degrees
Normalized name: NEEDLE 20G 1IN BENT 90 DEGREES
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 degrees tilt drug-free
Study: 11694895
Drug: 80 degrees
Normalized name: NEEDLE 20G 1IN BENT 90 DEGREES
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 degrees tilt drug-free
Study: 11694895
Drug: Isoproterenol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol infusion at 60 degrees
Study: 11694895
Drug: Isoproterenol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol infusion at 80 degrees
Study: 9126518
Drug: Injury prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injury prevention campaign on Naxos involving trained local collaborators providing weekly visits and advice.
Study: 3122880
Drug: Oral 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one (up to 100 mg/kg/day)
Study: 3122880
Drug: Oral 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one with ascorbic acid
Study: 3122880
Drug: Subcutaneous desferrioxamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous desferrioxamine (at comparable dose)
Study: 23939511
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day baclofen
Study: 23939511
Drug: 75 mg/day
Normalized name: Lyllana 0.075 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/day baclofen
Study: 23939511
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day baclofen (in pharmacokinetic and cue-reactivity component)
Study: 23939511
Drug: 75 mg/day
Normalized name: Lyllana 0.075 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/day baclofen (in pharmacokinetic and cue-reactivity component)
Study: 21560488
Drug: Siriraj Mite
Normalized name: mite extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siriraj Mite Allergen Vaccine (SMAV) Dp at 2,500 AU/ml
Study: 21560488
Drug: Siriraj Mite
Normalized name: mite extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siriraj Mite Allergen Vaccine (SMAV) Dp at 10,000 AU/ml
Study: 21560488
Drug: Siriraj Mite
Normalized name: mite extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siriraj Mite Allergen Vaccine (SMAV) Df at 10,000 AU/ml
Study: 21560488
Drug: Commercial standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial standardized mite allergen vaccine Dp at 2,500 AU/ml
Study: 21560488
Drug: Commercial standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial standardized mite allergen vaccine Df at all concentrations
Study: 15466644
Drug: Candesartan, titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan, titrated to 32 mg QD
Study: 9584032
Drug: Safe Dates
Normalized name: Date
DrugBank: Date (DB10632)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safe Dates program (treatment)
Study: 23593643
Drug: G1: no
Approvals — FDA: no, EMA: no, PMDA: no
Description: G1: no treatment
Study: 19393405
Drug: Liquid alginate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid alginate suspension
Study: 1446992
Drug: Flunarizine (Fz)
Normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (Fz) 10 mg/d
Study: 31524938
Drug: Adding diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adding diabetes medications; 410 participants rated importance of 7 factors.
Study: 31524938
Drug: Stopping diabetes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stopping diabetes medications; 408 participants rated importance of 7 factors.
Study: 21558567
Drug: Strength training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength training (TG; twice per week for 12 weeks)
Study: 20137540
Drug: Atorvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20 mg/d) and probucol (500 mg/d) for 4 weeks (combination group)
Study: 20137540
Drug: Atorvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20 mg/d) for 4 weeks (atorvastatin group)
Study: 20137540
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Atorvastatin and combination)
Study: 16316886
Drug: Tailored hypnotic
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tailored hypnotic induction
Study: 16316886
Drug: Manualized hypnotic
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manualized hypnotic induction (Palsson's protocol)
Study: 11575866
Drug: Rasagiline (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline (0.5, 1, and 2 mg/d)
Study: 9059469
Drug: CPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP therapy (for patients with best CPAP use)
Study: 9059469
Drug: CPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP therapy (compliance comparison)
Study: 7903218
Drug: Propranolol 160
Normalized name: propranolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 160 mg (SR)
Study: 29860473
Drug: Macimorelin (single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macimorelin (single-dose oral)
Study: 28270180
Drug: Active acupressure
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active acupressure therapy (PC6, LI4, HT7 acupressure performed three times a day for 2 days)
Study: 26009822
Drug: Subjective evaluation
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjective evaluation of sublingual microcirculation images by physicians and nurses
Study: 23534046
Drug: Fluorinex treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorinex treatment
Study: 21636013
Drug: Vitamin B₆
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B₆ intake (median daily intake of 0.9 mg/day, range 0.6-1.5 mg/day)
Study: 10891912
Drug: Naratriptan 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naratriptan 1.5 mg
Study: 8838506
Drug: Rheumatoid arthritis
Normalized name: Rheumatoid arthritis nuclear antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rheumatoid arthritis (RA) patients receiving low dose methotrexate (MTX)
Study: 8838506
Drug: Rheumatoid arthritis
Normalized name: Rheumatoid arthritis nuclear antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rheumatoid arthritis (RA) patients not receiving low dose methotrexate (MTX)
Study: 1486071
Drug: 0.3% gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% gentamicin ophthalmic solution
Study: 30191262
Drug: Laquinimod (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laquinimod (0.6 mg/day)
Study: 25515217
Drug: Multifaceted quality
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifaceted quality improvement intervention for CVD risk management including electronic decision support, patient risk communication tools, computerized audit and feedback tools, and monthly peer-ranked performance feedback via a web portal.
Study: 7985829
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g fish oil (group A)
Study: 7985829
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g placebo Italian olive oil (group B)
Study: 26093363
Drug: Intensive periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive periodontal disease treatment during mid-pregnancy (20-28 weeks' gestation)
Study: 26093363
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (same treatment postnatally)
Study: 26093363
Drug: Intensive periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive periodontal disease treatment
Study: 24434527
Drug: Bupropion 150
Normalized name: BUPROPION 150MG (SMK-C) 12HR SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion 150 mg/d as an open-label add-on therapy (n = 5)
Study: 24434527
Drug: Previous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous treatment (valproate and aripiprazole) without bupropion (n = 7)
Study: 23031335
Drug: Beta-blocker treatment
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker treatment for 3 months
Study: 23031335
Drug: Combined alpha/beta-blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined alpha/beta-blocker treatment for 3 months
Study: 11529364
Drug: Kenacort‐A injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kenacort‐A injection into the right tonsillar fossa
Study: 19752608
Drug: Intrarectal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarectal lidocaine gel and 5 ml bupivacaine (0.25%) injected into periprostatic area
Study: 19752608
Drug: Intrarectal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarectal lidocaine gel and 5 ml ropivacaine (0.25%) injected into periprostatic area
Study: 17697548
Drug: TACE plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE plus thalidomide (200 mg/d for 1-6 months)
Study: 14973801
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron supplementation with iron III‐hydroxide sucrose complex (IHSC)
Study: 14973801
Drug: IV iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV iron and a single dose of r‐HuEPO (300 U/kg)
Study: 11214126
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg sulphate oral glucosamine once daily for 3 years
Study: 11214126
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 3 years
Study: 6937788
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml cows' milk (double-blind challenge)
Study: 28502735
Drug: Low calcium
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calcium dialysate (LCD; 1.25mmol/L)
Study: 28502735
Drug: Standard calcium
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard calcium dialysate (SCD; 1.5mmol/L)
Study: 22483238
Drug: Taeumjowi-tang (TJ001)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taeumjowi-tang (TJ001) 7 g three times daily for 12 weeks
Study: 20400000
Drug: Nasal oxygen
Normalized name: TUBE,NASAL OXYGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal oxygen administration
Study: 18074413
Drug: Rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg once a day
Study: 18074413
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg two times a day
Study: 18074413
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no hypoglycemic treatment)
Study: 10408729
Drug: MN rgp120
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: MN rgp120 HIV-1 vaccine (booster)
Study: 10408729
Drug: MN and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MN and IIIB rgp120 HIV-1 vaccines (coadministered)
Study: 8900242
Drug: Met-985 insulin-receptor
Normalized name: Met
DrugBank: Methionine (DB00134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Met-985 insulin-receptor variant
Study: 8900242
Drug: Normal oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal oral glucose tolerance test
Study: 6143187
Drug: 0.1 ml
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml intradermally at 8 sites
Study: 6143187
Drug: 8-site intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-site intradermal vaccination with large dose of HRIG
Study: 30365961
Drug: CPB flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPB flow rate of 2.4 L · min‐1 · m‐2
Study: 30365961
Drug: CPB flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPB flow rate of 2.7 L · min‐1 · m‐2
Study: 30365961
Drug: CPB flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPB flow rate of 3.0 L · min‐1 · m‐2
Study: 30365961
Drug: CPB flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPB flow rates of 2.4, 2.7, and 3.0 L · min‐1 · m‐2
Study: 30285672
Drug: Transdiagnostic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdiagnostic group cognitive-behaviour therapy (tCBT) - 12 weekly 2-hour group sessions following a manualized treatment protocol
Study: 21055582
Drug: Fixed orthodontic
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed orthodontic treatment with chemically cured resin
Study: 21055582
Drug: Fixed orthodontic
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed orthodontic treatment with light-cured resin
Study: 17986056
Drug: Low-dose UVA1
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose UVA1 phototherapy (40 J/cm²), 3 times weekly for 14 weeks
Study: 16179665
Drug: Modafinil split
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil split doses
Study: 16179665
Drug: Modafinil once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil once-daily (200 mg)
Study: 12487756
Drug: Medication plus
Normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication plus 1 g/day Spirulina (group II)
Study: 12487756
Drug: Medication (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (group I)
Study: 7621847
Drug: Diltiazem formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem formulation 1
Study: 7621847
Drug: Diltiazem formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem formulation 2
Study: 2196108
Drug: Corynebacterium parvum
Normalized name: Corynebacterium parvum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corynebacterium parvum (CP) plus chemotherapy (l-phenylalanine mustard (L-PAM) and 5-fluorouracil (PF))
Study: 2196108
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (l-phenylalanine mustard (L-PAM) and 5-fluorouracil (PF))
Study: 100818
Drug: Oral methylphenidate
Normalized name: methylphenidate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methylphenidate (1.0 mg/kg)
Study: 30799062
Drug: Directly observed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly observed treatment (DOT)
Study: 28962734
Drug: Combined orthodontic-periodontic
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined orthodontic-periodontic treatment
Study: 28962734
Drug: Basic periodontic
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic periodontic treatment
Study: 23430315
Drug: Cholecalciferol (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (2000 IU daily for 6 weeks)
Study: 19801932
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of L-alanine-L-glutamine dipeptide (0.40 g/kg/d; equal to 0.25 g of free glutamine) in Ala-Glu group (n = 212)
Study: 29976501
Drug: Consolidation chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation chemotherapy (2 cycles of capecitabine and oxaliplatin: capecitabine 1700 mg/m2 per day from day 1 to 14, oxaliplatin 100 mg/m2 on day 1, every 3 weeks) after CRT.
Study: 29976501
Drug: Preoperative chemoradiation
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemoradiation therapy (CRT) with capecitabine (50.4 Gy in 28 fractions) followed by TME.
Study: 27871086
Drug: Foam cream
Normalized name: Rectal Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foam cream (active agent)
Study: 27871086
Drug: Placebo foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo foam cream
Study: 24762588
Drug: Omeprazole, amoxicillin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, amoxicillin, and clarithromycin for 1 week (T group)
Study: 20485956
Drug: 4 mL
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL of hyperbaric bupivacaine (10 mg) and sufentanil (5 microg)
Study: 20485956
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL of hyperbaric bupivacaine (10 mg) and sufentanil (5 microg)
Study: 11952807
Drug: BQ‐123 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: BQ‐123 (60 microg min(‐1)), a specific ETA‐receptor antagonist
Study: 11952807
Drug: Ang II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ang II (0.65, 1.25, 2.5, 5 ng kg(‐1) min(‐1) for 15 min per dose level)
Study: 10732594
Drug: Kogan's (1961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kogan's (1961) Attitude Toward Old People's Scale administered before clinical experiences
Study: 10732594
Drug: Kogan's (1961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kogan's (1961) Attitude Toward Old People's Scale administered after clinical experiences
Study: 7677537
Drug: Steroid regimen:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid regimen: 1 g of methylprednisolone sodium succinate intravenously before bypass and 4 mg of dexamethasone every 6 hours for four doses during the first 24 hours of recovery.
Study: 2209305
Drug: Clonidine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.1 and 0.2 mg/day)
Study: 2209305
Drug: Pentoxifylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (400 mg 3 times/day)
Study: 775954
Drug: Intravenous digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous digoxin (0.01 mg/kg over 10 minutes)
Study: 28662677
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiotherapy (SBRT) with pembrolizumab (200 mg intravenously, every 3 weeks)
Study: 23808756
Drug: Prescription headache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription headache medication
Study: 21854276
Drug: Exercise as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise as an augmentation treatment
Study: 8183752
Drug: Subcutaneous fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous fluid therapy (2 litres of dextrose-saline/24 hours)
Study: 8183752
Drug: Intravenous fluid
Normalized name: Intravenous fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluid therapy (2 litres of dextrose-saline/24 hours)
Study: 8183752
Drug: Subcutaneous fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous fluid therapy
Study: 3070826
Drug: Ethamsylate (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethamsylate (2 g/day in four equal doses)
Study: 31865579
Drug: Plant-derived compounds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant-derived compounds with larvicidal activity; specific compounds not detailed
Study: 29257140
Drug: Amitriptyline (AMI;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (AMI; 50 mg)
Study: 29257140
Drug: Escitalopram (ESC;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (ESC; 10 mg)
Study: 28160761
Drug: Nartana herbal
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nartana herbal formulation (450 mg, 2 ×/d for first 15 d, then 1 ×/d)
Study: 28160761
Drug: Diclofenac (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (50 mg, 2 ×/d for first 15 d, then 100 mg, 1 ×/d)
Study: 16918762
Drug: Dronabinol (DRO)
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dronabinol (DRO) 5 mg b.i.d.
Study: 11197587
Drug: Zanamivir 10
Normalized name: Zanamivir 10 mg/mL solution for infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanamivir 10 mg inhaled twice daily
Study: 11197587
Drug: Oseltamivir 75
Normalized name: oseltamivir 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 75 mg orally twice daily
Study: 11197587
Drug: Zanamivir 10
Normalized name: Zanamivir 10 mg/mL solution for infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanamivir 10 mg inhaled once daily for prophylaxis
Study: 11197587
Drug: Oseltamivir 75
Normalized name: oseltamivir 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 75 mg orally once daily for prophylaxis
Study: 9103722
Drug: Daily urge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily urge intensity measures
Study: 7957037
Drug: Inhaled ipratropium
Normalized name: ipratropium Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled ipratropium bromide (160 micrograms, dry powder) added to stimulation in one patient with obstructive lung disease
Study: 3066896
Drug: Amitriptyline or
Normalized name: amitriptyline Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline or Imipramine treatment
Study: 31549943
Drug: Machine learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine learning (ML)‐based CT fractional flow reserve (FFR)
Study: 23681144
Drug: Automated alert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated alert recommending lung-protective ventilation with a Vt of 6 cc/kg predicted body weight
Study: 17573205
Drug: Enhanced cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced cognitive-behavioral therapy (MET+CBT)
Study: 9495400
Drug: ondansetron (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron (0.1 mg/kg, n = 26)
Study: 9495400
Drug: dimenhydrinate (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: dimenhydrinate (0.5 mg/kg, n = 25)
Study: 7852614
Drug: 0.1% methylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% methylene blue gel irrigated at 0, 1, and 4 weeks